Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 418 | 404 | 466 | 528 | 622 |
| Accounts payable and accrued liabilities | 1,653 | -4,788 | -280 | 4,627 | -472 |
| Other Working Capital | 2,168 | -11,025 | 2,810 | 4,317 | 1,516 |
| Other Operating Activity | -26,229 | -20,568 | -47,586 | -41,794 | -44,970 |
| Operating Cash Flow | $-21,990 | $-35,977 | $-44,590 | $-32,322 | $-43,304 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | 18 | -29 | -24 | -212 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -34,996 |
| Other Investing Activity | 0 | 0 | 9,989 | 30,090 | 0 |
| Investing Cash Flow | $0 | $18 | $9,960 | $30,066 | $-35,208 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 18,650 | 10,000 | N/A | N/A | N/A |
| Debt Repayment | -100 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 828 | 23,407 | 6,881 | 101 | 36 |
| Common Stock Repurchased | 0 | -21 | N/A | N/A | N/A |
| Other Financing Activity | 1 | 28 | 29 | 15 | 190 |
| Financing Cash Flow | $19,379 | $33,414 | $6,910 | $116 | $226 |
| Exchange Rate Effect | N/A | 0 | 2 | -4 | 7 |
| Beginning Cash Position | 6,707 | 9,252 | 36,970 | 39,114 | 117,393 |
| End Cash Position | 4,096 | 6,707 | 9,252 | 36,970 | 39,114 |
| Net Cash Flow | $-2,611 | $-2,545 | $-27,720 | $-2,140 | $-78,286 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,990 | -35,977 | -44,590 | -32,322 | -43,304 |
| Capital Expenditure | N/A | -5 | -29 | -24 | -212 |
| Free Cash Flow | -21,990 | -35,982 | -44,619 | -32,346 | -43,516 |